Top in endocrinology: Odds of weight loss in adults; FDA approval of bone disease therapy

Adults with overweight or obesity had a 10% annual probability of achieving 5% or greater weight loss, according to study data published in JAMA Network Open.

“This is one of the only papers to assess the probability of a 5% weight loss or reducing BMI to healthy weight among U.S. adults with overweight and obesity. Results suggest that 5% weight loss is more attainable at higher BMIs,” Lyudmyla Kompaniyets, PhD, health economist in the division of nutrition, physical activity and obesity at the CDC, told Healio. “Given the health benefits of clinically meaningful weight reduction at any level of excess weight, 5% or greater weight loss can be a reasonable target for obesity management efforts.”

It was the top story in endocrinology last week.

The second top story was about the FDA approval of Sohonos (palovarotene, Ipsen) for the treatment of fibrodysplasia ossificans progressive in adult and pediatric patients. In a phase 3 trial, the medication reduced heterotopic ossification volume by 54%.

Read these and more top stories in endocrinology below:

Odds of losing 5% or more body weight low in adults with overweight or obesity

Adults with overweight or obesity in the U.S. have a one in 10 annual probability of achieving a 5% or greater weight loss, and the likelihood for weight loss increases with a higher initial BMI, according to study data. Read more.

FDA approves oral palovarotene as first treatment for rare bone disease

The FDA approved palovarotene capsules as the first treatment for people with the rare bone disease fibrodysplasia ossificans progressiva, according to an industry press release. Read more.

Growth hormone lowers liver fat for adults with obesity, steatotic liver disease

Adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease had a more than 5% reduction in liver fat at 6 months with growth hormone therapy, according to findings from a randomized controlled trial. Read more.

SGLT2 inhibitors preferred for adults with type 2 diabetes and heart failure

SGLT2 inhibitors should be the first choice of therapy for adults with type 2 diabetes and heart failure, according to two speakers at the Association of Diabetes Care and Education Specialists annual meeting. Read more.

Smoking, little physical activity increase risk for lower limb amputations in diabetes

Adults with diabetes who smoke or exercise less than once per week are among those at higher risk for a lower limb amputation, but adults with obesity may have a lower risk for amputations, according to study data. Read more.